115 related articles for article (PubMed ID: 29573035)
1. Synthesis and physicochemical studies of amyloidogenic hexapeptides derived from human cystatin C.
Iłowska E; Sawicka J; Szymańska A
J Pept Sci; 2018 Jun; 24(4-5):e3073. PubMed ID: 29573035
[TBL] [Abstract][Full Text] [Related]
2. Exploring the 'aggregation-prone' core of human Cystatin C: A structural study.
Tsiolaki PL; Louros NN; Hamodrakas SJ; Iconomidou VA
J Struct Biol; 2015 Sep; 191(3):272-80. PubMed ID: 26235923
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of human cystatin C stabilized against amyloid formation.
Kolodziejczyk R; Michalska K; Hernandez-Santoyo A; Wahlbom M; Grubb A; Jaskolski M
FEBS J; 2010 Apr; 277(7):1726-37. PubMed ID: 20175878
[TBL] [Abstract][Full Text] [Related]
4. Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C.
Orlikowska M; Jankowska E; Kołodziejczyk R; Jaskólski M; Szymańska A
J Struct Biol; 2011 Feb; 173(2):406-13. PubMed ID: 21074623
[TBL] [Abstract][Full Text] [Related]
5. The pentapeptide LQVVR plays a pivotal role in human cystatin C fibrillization.
Tsiolaki PL; Hamodrakas SJ; Iconomidou VA
FEBS Lett; 2015 Jan; 589(1):159-64. PubMed ID: 25479090
[TBL] [Abstract][Full Text] [Related]
6. The role of the Val57 amino-acid residue in the hinge loop of the human cystatin C. Conformational studies of the beta2-L1-beta3 segments of wild-type human cystatin C and its mutants.
Rodziewicz-Motowidło S; Iwaszkiewicz J; Sosnowska R; Czaplewska P; Sobolewski E; Szymańska A; Stachowiak K; Liwo A
Biopolymers; 2009 May; 91(5):373-83. PubMed ID: 19137579
[TBL] [Abstract][Full Text] [Related]
7. Effect of antisense peptide binding on the dimerization of human cystatin C--gel electrophoresis and molecular modeling studies.
Stachowiak K; Rodziewicz-Motowidło S; Sosnowska R; Kasprzykowski F; Łankiewicz L; Grubb A; Grzonka Z
Acta Biochim Pol; 2004; 51(1):153-60. PubMed ID: 15094836
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of antibodies elicited by human cystatin C fragment.
Behrendt I; Prądzińska M; Spodzieja M; Czaplewska P; Kołodziejczyk AS; Szymańska A; Kasprzykowski F; Lundström SL; Zubarev RA; Rodziewicz-Motowidło S
J Mol Recognit; 2018 Apr; 31(4):. PubMed ID: 29205549
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Steric Zipper Motif in the Amyloidogenic Core of Human Cystatin C and Its Use for the Design of Self-Assembling Peptides.
Iłowska E; Barciszewski J; Jaskólski M; Moliński A; Kozak M; Szymańska A
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628610
[TBL] [Abstract][Full Text] [Related]
10. Human cystatin C monomer, dimer, oligomer, and amyloid structures are related to health and disease.
Jurczak P; Groves P; Szymanska A; Rodziewicz-Motowidlo S
FEBS Lett; 2016 Dec; 590(23):4192-4201. PubMed ID: 27766618
[TBL] [Abstract][Full Text] [Related]
11. Domain swapping in N-truncated human cystatin C.
Janowski R; Abrahamson M; Grubb A; Jaskolski M
J Mol Biol; 2004 Jul; 341(1):151-60. PubMed ID: 15312769
[TBL] [Abstract][Full Text] [Related]
12. NAC blocks Cystatin C amyloid complex aggregation in a cell system and in skin of HCCAA patients.
March ME; Gutierrez-Uzquiza A; Snorradottir AO; Matsuoka LS; Balvis NF; Gestsson T; Nguyen K; Sleiman PMA; Kao C; Isaksson HJ; Bragason BT; Olafsson E; Palsdottir A; Hakonarson H
Nat Commun; 2021 Mar; 12(1):1827. PubMed ID: 33758187
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of C-terminal, β-amyloid peptide binding fragment of neuroprotective protease inhibitor, cystatin C.
Spodzieja M; Kalejta K; Kołodziejczyk AS; Maszota-Zieleniak M; Rodziewicz-Motowidło S; Żmudzińska W; Czaplewska P
J Mol Recognit; 2017 Feb; 30(2):. PubMed ID: 27714883
[TBL] [Abstract][Full Text] [Related]
14. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping.
Janowski R; Kozak M; Jankowska E; Grzonka Z; Grubb A; Abrahamson M; Jaskolski M
Nat Struct Biol; 2001 Apr; 8(4):316-20. PubMed ID: 11276250
[TBL] [Abstract][Full Text] [Related]
15. Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C: use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C.
Nilsson M; Wang X; Rodziewicz-Motowidlo S; Janowski R; Lindström V; Onnerfjord P; Westermark G; Grzonka Z; Jaskolski M; Grubb A
J Biol Chem; 2004 Jun; 279(23):24236-45. PubMed ID: 15028721
[TBL] [Abstract][Full Text] [Related]
16. Epitope location for two monoclonal antibodies against human cystatin C, representing opposite aggregation inhibitory properties.
Behrendt I; Prądzińska M; Spodzieja M; Kołodziejczyk AS; Rodziewicz-Motowidło S; Szymańska A; Czaplewska P
Amino Acids; 2016 Jul; 48(7):1717-29. PubMed ID: 27143169
[TBL] [Abstract][Full Text] [Related]
17. Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping.
Wahlbom M; Wang X; Lindström V; Carlemalm E; Jaskolski M; Grubb A
J Biol Chem; 2007 Jun; 282(25):18318-18326. PubMed ID: 17470433
[TBL] [Abstract][Full Text] [Related]
18. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type.
Calero M; Pawlik M; Soto C; Castaño EM; Sigurdsson EM; Kumar A; Gallo G; Frangione B; Levy E
J Neurochem; 2001 Apr; 77(2):628-37. PubMed ID: 11299325
[TBL] [Abstract][Full Text] [Related]
19. Influence of point mutations on the stability, dimerization, and oligomerization of human cystatin C and its L68Q variant.
Szymańska A; Jankowska E; Orlikowska M; Behrendt I; Czaplewska P; Rodziewicz-Motowidło S
Front Mol Neurosci; 2012; 5():82. PubMed ID: 22866027
[TBL] [Abstract][Full Text] [Related]
20. Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: why is the L68Q variant amyloidogenic?
Rodziewicz-Motowidło S; Wahlbom M; Wang X; Lagiewka J; Janowski R; Jaskólski M; Grubb A; Grzonka Z
J Struct Biol; 2006 Apr; 154(1):68-78. PubMed ID: 16446102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
